Toms River R&D Tax Credit Benefits for Businesses

R&D Tax Credits for Toms River, New Jersey Businesses

Toms River, New Jersey, thrives in industries such as healthcare, education, retail, manufacturing, and tourism. Top companies in the city include Community Medical Center, a leading healthcare provider; Ocean County College, a major educational institution; Walmart, a significant retail employer; BASF, a key player in the manufacturing sector; and the Jersey Shore, a prominent tourism attraction. The R&D Tax Credit can provide tax savings for these industries by incentivizing innovation and technological advancements.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 100 Horizon Center Boulevard, Hamilton, New Jersey is less than 35 miles away from Toms River ans provides R&D tax credit consulting and advisory services to Toms River and the surrounding areas such as: Lakewood Township, Brick Township, Middletown Township, Old Bridge Township and Jackson Township.

If you have any questions or need further assistance, please call or email our local New Jersey Partner on (609) 900-2488.
Feel free to book a quick teleconference with one of our New Jersey R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Toms River, New Jersey Patent of the Year – 2024/2025

Taran Therapeutics, Inc. has been awarded the 2024/2025 Patent of the Year for their breakthrough in treating chronic myelomonocytic leukemia (CMML). Their invention, detailed in U.S. Patent Application No. 20240309079, titled ‘Combination treatment of chronic myelomonocytic leukemia in patients with RAS pathway mutations’, offers a novel approach to combat this aggressive cancer.

CMML, a rare and challenging form of leukemia, often presents with mutations in the RAS signaling pathway, including NRAS, KRAS, and CBL genes. These mutations are associated with poor prognosis and resistance to standard treatments. Taran Therapeutics’ innovative method involves identifying these RAS pathway mutations in tumor cells and administering a combination therapy.

The proposed treatment includes an anti-hGM-CSF antibody, such as lenzilumab, which targets a specific cytokine involved in leukemia cell proliferation. When combined with a hypomethylating agent like azacitidine, this therapy has shown promising results. Clinical data indicate that this combination can achieve a complete or partial response rate of 50-90%, significantly higher than the 10-17% response rate seen with hypomethylating agents alone.

This dual-targeted approach represents a significant advancement in personalized medicine for CMML patients, offering hope for more effective treatments and improved outcomes in this challenging disease.